Visceral fat endocannabinoid overproduction is associated with insulin resistance and tissue dysfunction in mice and humans

Insulin resistance and severe metabolic dysregulation of adipocytes—rather than total fat mass alone—drive depot-specific endocannabinoid overproduction. Visceral adipose tissue acts as a primary source for elevated systemic endocannabinoid levels in type 2 diabetes, presenting a target for tissue-specific cannabinoid receptor type 1 ($\text{CB}_1$) signaling therapies to alleviate downstream metabolic complications.